Amgen (AMGN) Earnings Date & Reports

Amgen posted total revenues of $8.618 billion for the first quarter ended March 31, 2026, exceeding analyst consensus of about $8.49 billion and up 6% from $8.149 billion in the prior-year period. Product sales, the core revenue driver, reached $8.218 billion, a 4% YoY increase fueled by 9% volume growth, partially offset by lower net selling prices and inventory levels.

GAAP (Generally Accepted Accounting Principles, standard accounting rules) diluted EPS rose 4% to $3.34 from $3.20 YoY, while non-GAAP diluted EPS climbed 5% to $5.15 from $4.90, topping expectations near $4.75. Operating margins improved on the GAAP basis to 32.4%, boosted by higher revenues, though non-GAAP margins dipped slightly to 45.3%.

Key metrics shone with 16 products posting double-digit growth, led by IMDELLTRA (up 219% to $258 million), UPLIZNA (up 188% to $262 million), Repatha (up 34% to $876 million), and TEPEZZA (up 29% to $490 million). Offsetting declines included Prolia (down 34% to $727 million), Enbrel (down 37% to $320 million), and XGEVA (down 27% to $411 million), tied to competition and pricing. Guidance for 2026 remained steady, signaling confidence.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.

Market Reaction and Investor Sentiment

Amgen shares climbed 2.4% to $346.25 on April 30, 2026, reflecting positive investor response to the earnings beat and reaffirmed guidance. Sentiment focused on volume-driven growth across newer brands offsetting declines in legacy products, with analysts noting the portfolio's breadth as a key strength amid patent cliffs.

Forward Outlook and Key Factors to Monitor

Amgen's reaffirmed 2026 guidance points to total revenues of $37.1 billion to $38.5 billion and non-GAAP EPS of $21.70 to $23.10, aligning with prior expectations and supported by pipeline momentum. Investors should track uptake in high-growth products like Repatha, TEZSPIRE, and IMDELLTRA, which demonstrated strong volume expansion this quarter.

Challenges persist for mature assets such as Prolia and Enbrel, where biosimilar erosion and pricing pressures could intensify. Upcoming catalysts include label expansions, regulatory approvals for pipeline candidates in oncology and rare diseases, and progress on cost management amid elevated R&D (research and development) spending.

Broader dynamics like U.S. drug pricing policies, reimbursement trends, and global demand signals for inflammation therapies will shape margins. Free cash flow generation remains robust at $1.5 billion in Q1, supporting up to $3.0 billion in share repurchases and a $2.6 billion capex plan. Monitoring these elements will provide clarity on Amgen's execution through 2026.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations